MTVA Stock Overview
A clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
MetaVia Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.76 |
| 52 Week High | US$6.75 |
| 52 Week Low | US$1.51 |
| Beta | -0.26 |
| 1 Month Change | -25.42% |
| 3 Month Change | -46.99% |
| 1 Year Change | -52.39% |
| 3 Year Change | -99.40% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation
Oct 03
NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Sep 29Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely
Sep 14NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split
Sep 12NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases
Nov 25NeuroBo on track to post a record gain after announcing a special meeting
Jun 14NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition
Jan 06Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like
Dec 21NeuroBo Pharmaceuticals EPS misses by $0.02
Nov 13Shareholder Returns
| MTVA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.0% | 2.6% | 2.8% |
| 1Y | -52.4% | -3.3% | 24.6% |
Return vs Industry: MTVA underperformed the US Biotechs industry which returned -3.3% over the past year.
Return vs Market: MTVA underperformed the US Market which returned 24.6% over the past year.
Price Volatility
| MTVA volatility | |
|---|---|
| MTVA Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MTVA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MTVA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 8 | Hyung-Heon Kim | www.metaviatx.com |
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia.
MetaVia Inc. Fundamentals Summary
| MTVA fundamental statistics | |
|---|---|
| Market cap | US$15.59m |
| Earnings (TTM) | -US$27.73m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs MTVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MTVA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$27.73m |
| Earnings | -US$27.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MTVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 02:19 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MetaVia Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Robert LeBoyer | Ladenburg Thalmann & Company |
| Aydin Huseynov | Ladenburg Thalmann & Company |